Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'ivoire

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Pasquet, Armelle ^a   Messou, Eugène ^b   Gabillard, Delphine ^c   Minga, Albert ^c,d   Depoulosky, Ayeby ^b   Deuffic Burban, Sylvie ^e,f   Losina, Elena ^g   Freedberg, Kenneth A ^g   Danel, Christine ^c,d   Anglaret, Xavier ^c,d   Yazdanpanah, Yazdan ^a,f  

^a CENTRE HOSPITALIER DE TOURCOING   (France)

^b ACONDA   (Côte d’Ivoire)

^c INSERM   (France)

^d Programme PAC CI   (Côte d’Ivoire)

^e UNIVERSITÉ DE LILLE   (France)

^f UNIV LILLE   (France)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; COTE D'IVOIRE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE FACILITY; HOSPITAL PHARMACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; PROPORTIONAL HAZARDS MODEL;

ADULT; ANTI-HIV AGENTS; COTE D'IVOIRE; HIV INFECTIONS; HUMANS; PROPORTIONAL HAZARDS MODELS;

EID: 78149463300     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013414     Document Type: Article

References (38)

1. UNAIDS/WHO (2008) Report on the global AIDS epidemic. Geneva.
2. News in brief (2003) US Senate approves AIDS bill. Lancet 361: 1799.
3. Walgate R (2002) Global Fund for AIDS, TB and malaria opens shop. Bull World Health Organ 80: 259.
4. WHO/UNAIDS/UNICEF (2007) Towards Universal Acces. Scaling up priority HIV/AIDS interventions in the health sector. Progress report.
5. Fischer A, Karasi JC, Kibibi D, Omes C, Lambert C, et al. (2006) Antiviral efficacy and resistance in patients on antiretroviral therapy in Kigali, Rwanda: the real-life situation in 2002. HIV Med 7: 64-66.
6. Eholie SP, Tanon A, Polneau S, Ouiminga M, Djadji A, et al. (2007) Field adherence to highly active antiretroviral therapy in HIV-infected adults in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 45: 355-358.
7. Diabate S, Alary M, Koffi CK (2007) Determinants of adherence to highly active antiretroviral therapy among HIV-1-infected patients in Cote d'Ivoire. Aids 21: 1799-1803.
8. Weidle PJ, Wamai N, Solberg P, Liechty C, Sendagala S, et al. (2006) Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 368: 1587-1594.
9. Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, et al. (2007) Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. Aids 21: 965-971.
10. Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, et al. (2002) Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 30: 105-110.
11. Geye A, Seyler C (2007) Case study country: Cote d'Ivoire. Strategies for Building National-Scale Longitudinal Patient Monitoring Systems for HIV Treatment and Care in PEPFAR Countrie; Workshop, Lusaka, Zambia.
12. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, et al. (2008) Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2- year outcomes and determinants. Aids 22: 873-882.
13. Minga A, Danel C, Abo Y, Dohoun L, Bonard D, et al. (2007) Progression to WHO criteria for antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Cote d'Ivoire. Bull World Health Organ 85: 116-123.
14. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, et al. (2002) Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 360: 34-40.
15. Anglaret X, Toure S, Gourvellec G, Tchehy A, Zio L, et al. (2004) Impact of vital status investigation procedures on estimates of survival in cohorts of HIVinfected patients from Sub-Saharan Africa. J Acquir Immune Defic Syndr 35: 320-323.
16. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, et al. (2008) Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lowerincome countries. Bull World Health Organ 86: 559-567.
17. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. Jama 296: 782-793.
18. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817-824.
19. Dalal RP, Macphail C, Mqhayi M, Wing J, Feldman C, et al. (2008) Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in johannesburg, South Africa. J Acquir Immune Defic Syndr 47: 101-107.
20. Rosen S, Fox MP, Gill CJ (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 4: e298.
21. Crow E, Gardner R (1959) confidence intervals for the expectation of a poisson variable Biometrika 46: 441-453.
22. Gail MH (1972) Does cardiac transplantation prolong life? A reassessment. Ann Intern Med 76: 815-817.
23. Menard Scott MS (1995) Applied Logistic Regression Analysis: SAGE publications.
24. Harries AD, Schouten EJ, Makombe SD, Libamba E, Neufville HN, et al. (2007) Ensuring uninterrupted supplies of antiretroviral drugs in resource-poor settings: an example from Malawi. Bull World Health Organ 85: 152-155.
25. WHO (2009) Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents.
26. Martin WG, Brinkhof FD, Myer L, Bangsberg DR, Boulle A, et al. (2008) Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 86: 497-576.
27. Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, et al. (2006) Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. Aids 20: 41-48.
28. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, et al. (2006) Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. Aids 20: 1163-1169.
29. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, et al. (2006) Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 43: 770-776.
30. Tuboi SH, Harrison LH, Sprinz E, Albernaz RK, Schechter M (2005) Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. J Acquir Immune Defic Syndr 40: 324-328.
31. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, et al. (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367: 1335-1342.
32. De Beaudrap P, Etard JF, Ecochard R, Diouf A, Dieng AB, et al. (2008) Change over time of mortality predictors after HAART initiation in a Senegalese cohort. Eur J Epidemiol 23: 227-234.
33. Keiser O, Fellay J, Opravil M, Hirsch HH, Hirschel B, et al. (2007) Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. Antivir Ther 12: 1157-1164.
34. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, et al. (2008) Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 197: 1133-1144.
35. Cesar C, Shepherd BE, Krolewiecki AJ, Fink VI, Schechter M, et al. (2010) Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America. PLoS One 5: e10490.
36. Boulle A, Orrel C, Kaplan R, Van Cutsem G, McNally M, et al. (2007) Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 12: 753-760.
37. Messou E, Anglaret X, Duvignac J, Konan-N'dri E, Komena E, et al. (2010) Antiretroviral treatment changes in adults from Cote d'Ivoire: the roles of tuberculosis and pregnancy. Aids 24: 93-99.
38. Laniece I, Ciss M, Desclaux A, Diop K, Mbodj F, et al. (2003) Adherence to HAART and its principal determinants in a cohort of Senegalese adults. Aids 17 Suppl 3: S103-108.